REVENUE

12 Months Ended

Dec. 31, 2023

REVENUE

REVENUE

NOTE 8 - REVENUE

The following table summarizes the Company’s disaggregation of revenues:

	Year Ended December 31,
(U.S. dollars in thousands)	2021		2022		2023
Pfizer	$	10,160	$	12,403	$	12,522
Brazil	$	6,400	$	9,452	$	10,401
Chiesi		189	$	3,437	$	17,495
Total revenues from selling goods	$	16,749	$	25,292	$	40,418
Revenues from license and R&D services	$	21,601	$	22,346	$	25,076

During the year ended December 31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.